Experimental drug aims to keep viral pneumonia patients out of hospital
NCT ID NCT06202521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested the drug silmitasertib (CX-4945) plus standard care in adults with pneumonia caused by COVID-19 or influenza. The goal was to see if the drug could reduce the need for hospitalization or prevent death. The study planned to enroll 120 people but was terminated early after enrolling 45. Participants took the drug or a placebo twice daily for up to 5 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
silmitasertib (CX-4945)
What this could lead to
If it worked, this could point toward a new treatment to prevent hospitalization and death from viral pneumonia caused by COVID-19 or flu.
What could go wrong
The trial was terminated early with only 45 participants, so results are limited. It is a Phase 2 study, meaning it is still early and may not show clear benefit or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMUNITY-ACQUIRED PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Far Eastern Memorial Hospital
New Taipei City, Taiwan
-
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
-
National Taiwan University Cancer Center, National Taiwan University Hospital
Taipei, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taoyuan General Hospital, Ministry of Health and Welfare
Taoyuan, Taiwan
-
Tri-Service General Hospital
Taipei, Taiwan